These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
133 related articles for article (PubMed ID: 4627781)
1. Thyrotropin releasing hormone: enhancement of dopa activity by a hypothalamic hormone. Plotnikoff NP; Prange AJ; Breese GR; Anderson MS; Wilson IC Science; 1972 Oct; 178(4059):417-8. PubMed ID: 4627781 [TBL] [Abstract][Full Text] [Related]
2. Action of two hypothalamic factors (TRH, MIF) and of angiotensin II on the behavioral effects of L-DOPA and 5-hydroxytryptophan in mice. Huidobro-Toro JP; De Carolis AS; Longo VG Pharmacol Biochem Behav; 1974; 2(1):105-9. PubMed ID: 4364044 [No Abstract] [Full Text] [Related]
9. Gonadotropin-releasing hormone and thyrotropin-releasing hormone: distribution and effects in the central nervous system. Wilber JF; Montoya E; Plotnikoff NP; White WF; Gendrick R; Renaud L; Martin JB Recent Prog Horm Res; 1976; 32():117-59. PubMed ID: 822482 [No Abstract] [Full Text] [Related]
10. Intensification of central catecholaminergin and serotonergic processes by the hypothalamic factors MIF and TRF and by angiotensin II. Huidobro-Toro JP; Scotti de Carolis A; Longo VG Pharmacol Biochem Behav; 1975; 3(2):235-42. PubMed ID: 238221 [TBL] [Abstract][Full Text] [Related]
11. Functional evaluation of prolactin secretion: a guide to therapy. Friesen H; Guyda H; Hwang P; Tyson JE; Barbeau A J Clin Invest; 1972 Mar; 51(3):706-9. PubMed ID: 4622109 [TBL] [Abstract][Full Text] [Related]
12. TRH protection against memory retrieval deficits is independent of endocrine effects. Stwertka SA; Vincent GP; Gamzu ER; MacNeil DA; Verderese AG Pharmacol Biochem Behav; 1992 Jan; 41(1):145-52. PubMed ID: 1539064 [TBL] [Abstract][Full Text] [Related]
13. Synthetic MIF analogues. Part II: Dopa potentiation and fluphenazine antagonism. Voith K Arzneimittelforschung; 1977; 27(12):2290-3. PubMed ID: 23795 [TBL] [Abstract][Full Text] [Related]
14. Potentiation of the central nervous system effects of DOPA by decarboxylase inhibition: possible direct role of this neuroamino acid in brain mechanisms. Vazquez AJ; Sabelli HC Exp Neurol; 1975 Jan; 46(1):44-56. PubMed ID: 1109342 [No Abstract] [Full Text] [Related]
16. Study of the structural requirements for dopa potentiation and oxotremorine antagonism by L-prolyl-L-leucylglycinamide. Johnson RL; Smissman EE; Plotnikoff NP J Med Chem; 1978 Feb; 21(2):165-9. PubMed ID: 23433 [TBL] [Abstract][Full Text] [Related]
17. Release of thyroid stimulating hormone from chick anterior pituitary glands by thyrotropin releasing hormone (TRH). Breneman WR; Rathkamp W Biochem Biophys Res Commun; 1973 May; 52(1):189-94. PubMed ID: 4197189 [No Abstract] [Full Text] [Related]
18. Pharmaco-behavioral effects of hypothalamic peptides in animals and man: focus on thyrotropin-releasing hormone and neurotensin. Nemeroff CB; Loosen PT; Bissette G; Manberg PJ; Wilson IC; Lipton MA; Prange AJ Psychoneuroendocrinology; 1978 Oct; 3(3-4):279-310. PubMed ID: 34843 [No Abstract] [Full Text] [Related]
19. DOPA potentiation in ablated animals and brain levels of biogenic amines in intact animals after prolyl-leucylglycinamide. Plotnikoff NP; Minard FN; Kastin AJ Neuroendocrinology; 1974; 14(5):271-9. PubMed ID: 4858836 [No Abstract] [Full Text] [Related]
20. Prolactin and thyrotropin responses to thyrotropin-releasing hormone during the peripartal period. Miyamoto J Obstet Gynecol; 1984 May; 63(5):639-44. PubMed ID: 6425749 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]